Child died in Chinese biotech firm’s gene editing trial

A child's death following a gene-editing therapy trial in China has ignited fresh concerns over regulatory oversight and transparency in the country's rapidly growing biotechnology sector. The developer, Shanghai-based HuidaGene Therapeutics, stated that the child, who had Duchenne muscular dystrophy, died in August 2025 due to acute respiratory distress syndrome resulting from a severe immune reaction to the experimental therapy.

While HuidaGene did not identify the patient, clinical trial records indicate the study was exclusively for boys aged 4 to 8. This disclosure follows a months-long investigation by STAT News. The company has not provided immediate details on the therapy's future. The death was revealed weeks after a similar, previously unreported fatality in a young girl participating in a separate investigator-initiated trial (IIT) came to light.

These incidents underscore the lack of transparency within China's IIT system. This system permits researchers at major hospitals to test novel therapies without seeking approval from the national drug regulator. Such studies have proliferated in recent years, accelerating the development of cutting-edge cell and gene therapies that are fueling China's biotech boom. However, these fatalities are expected to intensify scrutiny on whether safety reporting and public disclosure mechanisms have kept pace with the sector's swift expansion.

The deceased patient was the fourth and final participant to receive HuidaGene's HG302 therapy, which employs modified adeno-associated virus (AAV) vectors to deliver DNA-editing components. The patient received a high dose, a factor known to cause fatal immune reactions in other clinical trials globally, including those involving young boys with Duchenne. HuidaGene confirmed the fatal event was reported through the hospital's ethics and oversight processes within the required timeframe.